We propose that, once cancer cells spontaneously acquire cisplatin resistance, we can use a PARP inhibitor (instead of a still-controversial MYC inhibitor) to inhibit oncogenic MYC activity so that we can recover endogenous BIN1 expression and accompanying cisplatin sensitivity. The gene discussed is BIN1; the disease is cancer.